Nasus Pharma to Present Topline Analysis from NS002 Intranasal Epinephrine Powder Phase 2 Single and Repeat Dose Clinical Study

Core Insights - Nasus Pharma Ltd. is set to host a conference call and webcast on March 16, 2026, to present the topline analysis from the Phase 2 repeated dose clinical study of NS002, an intranasal powder epinephrine product candidate [1] Company Overview - Nasus Pharma is a clinical-stage pharmaceutical company focused on developing innovative intranasal powder products for acute medical conditions [4] - The NS002 product is being developed as a needle-free alternative to epinephrine autoinjectors for patients experiencing anaphylaxis [4] - The company's proprietary powder-based intranasal (PBI) technology aims for rapid and reliable drug delivery, utilizing the nasal cavity's vascular network for quick absorption [4] - The PBI formulation employs uniform spherical powder particles for broad dispersion and potentially faster absorption compared to liquid-based nasal products [4] Conference Call Details - The conference call will take place at 8:00 a.m. ET on March 16, 2026, and will include a question-and-answer session following the data presentation [1] - Individuals can register for the webcast through a provided link, and dial-in numbers for the conference call are available for both US and international participants [6]